Daniel Reyner

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner et al. · The Lancet Diabetes & Endocrinology · 2019 · 200 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Paola Fioretto, Stefano Del Prato, John B. Buse et al. · Diabetes Obesity and Metabolism · 2018 · 191 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

TCE Meta-Analyses: Wartenberg et al.'s Response.

Daniel Wartenberg, Daniel Reyner · Environmental Health Perspectives · 2000 · 21 citations · Full text

Public Health, Environmental Sciences, Environmental Health +4

Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies

Mark T. Dransfield, Nathaniel Marchetti, Ravi Kalhan et al. · Chronic Respiratory Disease · 2025 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials

Donald A. Mahler, Surya P. Bhatt, Tara Rheault et al. · Expert Review of Respiratory Medicine · 2024 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16